Sickle CellNCT01683968
Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis
An observational study of Sickle Cell, run by King Abdullah International Medical Research Center at 1 site in Saudi Arabia.
Trial summary
This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises. You will be asked to do echocardiography during and after your admission to the hospital. We will compare tow pictures and study the differences. Read more about this study
- Who is it for?
- Ages 14 years and older
- Conditions the study is for
- Sickle Cell
- How many people
- 216 participants
- Where
- 1 siteSaudi Arabia
- Study dates
- Sep 2012to Oct 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Adult patient admitted to the hospital with vaso-occlusive crisis
Who may be able to join
- Patients older than 18 years
- Diagnosis of acute vaso-occlusive crisis due to sickle cell disease.
- Informed consent
Who cannot join
- Congenital heart disease
- Long standing hypertension
Trial locations and contacts
1 site in 1 country.
Saudi Arabia1 site, 1 recruiting
- Recruiting
King Abdulaziz Hospital
Al-Ahsa, EP, 31982
Abdulsalam MA Alaithan, MD, 96635910000 ext. 33445, aithana@ngha.med.sa
About this study
This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises.
You will be asked to do echocardiography during and after your admission to the hospital. We will compare tow pictures and study the differences.
Read the detailed description
Sickle cell disease (SCD) is a common genetic disorder of hemoglobin synthesis. Although sickle disease is globally spread it is more common in sub-Saharan Africa, India, Saudi Arabia and Mediterranean countries1. In Saudi Arabia, the prevalence of sickle cell disease id 24 per 10,000 with a higher prevalence in eastern province 145 per 10,0002.
The vaso-occlusive crisis is the principal presentation of SCD3. Acute pain is the primary and most common symptom of vaso-occlusive crisis4. Pain management and fluid resuscitation are the mainstay therapy for the treatment of vaso-occlusive crisis5. Pulmonary edema has been reported as a complication of fluid therapy during acute crisis management6. However, the exact mechanism of pulmonary edema in this population is not fully understood. Recent studies have demonstrated the presence of diastolic dysfunction in patients with SCD. Diastolic dysfunction was reported in 18% of patients with SCD7. These studies were performed when the patients were not in vaso-occlusive crisis.
Objectives of the Study:
Study hypothesis: Previous studies have shown that the prevalence of diastolic dysfunction is 18% (14-17). These studies have evaluated the general population of SCD without the distention whether these evaluations were made during the acute crisis or not. Others have also demonstrated increased pulmonary pressure in this patient population (32,33) . We hypothesize that the degree of diastolic dysfunction gets worse during acute vaso-occlusive crisis and may translate to higher pulmonary artery pressure and/or development of pulmonary edema during fluid therapy Study Area/Setting King Abdulaziz Hospital Alhasa
The primary objective if the study is to evaluate the presence and the degree of diastolic dysfunction during the Vaso-occlusive crisis of sickle cell disease. This will be achieved by evaluating multiple echocardiography parameters in accordance with the American Society of Echocardiography (ASE) Guidelines 10. These parameters include: Mitral valve inflow Hemodynamic E/A ratio and deceleration time(DT), septal and lateral mitral annular velocities (e')by tissue Doppler, and left atrial volume. According to these parameters the diastolic function can be evaluated as normal or abnormal. If abnormal then the diastolic dysfunction can be subsequently classified into impaired relaxation, pseudo-normalization and restrictive physiology(10-13). These parameters are age related (see table 1). The La volume will be measured by area by Biplane area-length method according to the formula (0.85) *( A1*A2/L) Where is A1 is left atrial volume in 4chamer view, A2 is left atrial volume in 2 chamber view and L is the length measured form the back wall of the left atrium to the mitral valve hinge point(14).
The grading of diastolic dysfunction will be as follows:
- Grade I (impaired relaxation): E/A< 0.8, DT>200 ms, E/e' </= 8 and LA volume >34 ml/m2.
- Grade II (pseudo-normalization): E/A=0.8- 1.5, DT= 160-200 ms, E/e' = 9-12 and LA volume >34 ml/m2.
- Grade II (restrictive physiology): E/A >2, DT<160 ms, E/e'>/=13 and LA volume >34 ml/m2.
- In case of overlap of these parameters so that no single category can be assigned the diastolic function will be categorized as abnormal.
The pulmonary artery pressure will be determined non-invasively on echocardiography by measuring tricuspid regurgitation jet velocity and adding the estimated right atrial pressure (15-17).
Pulmonary edema will be diagnosed either clinically by the presence of fine inspiratory crepitations on chest examination and high jugular venous pressure, and radio graphically by the presence of venous congestion and/or Kerley B-lines after confirming the finding by consultant radiologist oncall (18-20).
The vaso-occlusive crisis will be diagnosed clinically be the presence of the classical symptoms of pain and dehydration in the absence of alternative diagnosis (21-23).
Controls: The follow up echo (second echo) will be used as a baseline to compare the findings in the acute crisis to. As it is difficult to decide who of the patients with SCD will develop the acute crisis, we decided to recruit patients presenting in acute crisis and redo the echo as a follow up and use the follow up echo as a baseline looking at the same parameters.
Study Design Prospective cross sectional study Sample Size 50% probability of having the outcome of interest. Assuming 10% drop rate the number of needed subject would be 216 patients to achieving 95% confidence, 7 % margin of error.
Sampling Technique A consecutive inpatient admission to medical ward will be enrolled in the study according to inclusion and exclusion criteria mentioned above.
Data Management and Analysis Plan The SPSS for Windows 19.0 programme (SPSS Inc, Chicago, Illinois) will be used for statistical analysis. The chi-square test was used to analyze categorical variables and the Student's t test was used to analyze parametric variables. A p-value of 0.05 or less was considered statistically significant.
- Conditions
- Sickle Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Sickle cell | Patient who are admitted with sickle cell crises |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Sep 2012 (estimated)
- Study startSep 2012
- Primary completionOct 2015 (estimated)
- Study completionOct 2015 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Sickle CellStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 216 participants (estimated)
Sponsor and investigators
- Lead sponsor
- King Abdullah International Medical Research Center
- Sponsor type
- University, hospital or other
- Collaborators
- King Abdulaziz Medical City
- Responsible party
- Principal investigator, Abdulsalam Alaithan, King Abdulaziz Medical City
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01683968
- Sponsor's protocol ID
- RE11/027
- Status last verified
- Sep 2012
- First submitted
- 8 Sep 2012
- Last updated
- 13 Sep 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 13 Sep 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis
- ClinicalTrials.gov ID
- NCT01683968
- Acronym / sponsor ID
- RE11/027
- Conditions
- Sickle Cell
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 216 participants (estimated)
- Lead sponsor
- King Abdullah International Medical Research CenterUniversity, hospital or other
- Collaborators
- King Abdulaziz Medical City
- Study start
- Sep 2012
- Primary completion
- Oct 2015 (estimated)
- Study completion
- Oct 2015 (estimated)
- First posted
- 12 Sep 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is designed to investigate the presence and absence of abnormal heart muscle contractions during sickle cell crises.
You will be asked to do echocardiography during and after your admission to the hospital. We will compare tow pictures and study the differences.
Detailed description
Sickle cell disease (SCD) is a common genetic disorder of hemoglobin synthesis. Although sickle disease is globally spread it is more common in sub-Saharan Africa, India, Saudi Arabia and Mediterranean countries1. In Saudi Arabia, the prevalence of sickle cell disease id 24 per 10,000 with a higher prevalence in eastern province 145 per 10,0002.
The vaso-occlusive crisis is the principal presentation of SCD3. Acute pain is the primary and most common symptom of vaso-occlusive crisis4. Pain management and fluid resuscitation are the mainstay therapy for the treatment of vaso-occlusive crisis5. Pulmonary edema has been reported as a complication of fluid therapy during acute crisis management6. However, the exact mechanism of pulmonary edema in this population is not fully understood. Recent studies have demonstrated the presence of diastolic dysfunction in patients with SCD. Diastolic dysfunction was reported in 18% of patients with SCD7. These studies were performed when the patients were not in vaso-occlusive crisis.
Objectives of the Study:
Study hypothesis: Previous studies have shown that the prevalence of diastolic dysfunction is 18% (14-17). These studies have evaluated the general population of SCD without the distention whether these evaluations were made during the acute crisis or not. Others have also demonstrated increased pulmonary pressure in this patient population (32,33) . We hypothesize that the degree of diastolic dysfunction gets worse during acute vaso-occlusive crisis and may translate to higher pulmonary artery pressure and/or development of pulmonary edema during fluid therapy Study Area/Setting King Abdulaziz Hospital Alhasa
The primary objective if the study is to evaluate the presence and the degree of diastolic dysfunction during the Vaso-occlusive crisis of sickle cell disease. This will be achieved by evaluating multiple echocardiography parameters in accordance with the American Society of Echocardiography (ASE) Guidelines 10. These parameters include: Mitral valve inflow Hemodynamic E/A ratio and deceleration time(DT), septal and lateral mitral annular velocities (e')by tissue Doppler, and left atrial volume. According to these parameters the diastolic function can be evaluated as normal or abnormal. If abnormal then the diastolic dysfunction can be subsequently classified into impaired relaxation, pseudo-normalization and restrictive physiology(10-13). These parameters are age related (see table 1). The La volume will be measured by area by Biplane area-length method according to the formula (0.85) *( A1*A2/L) Where is A1 is left atrial volume in 4chamer view, A2 is left atrial volume in 2 chamber view and L is the length measured form the back wall of the left atrium to the mitral valve hinge point(14).
The grading of diastolic dysfunction will be as follows:
- Grade I (impaired relaxation): E/A< 0.8, DT>200 ms, E/e' </= 8 and LA volume >34 ml/m2.
- Grade II (pseudo-normalization): E/A=0.8- 1.5, DT= 160-200 ms, E/e' = 9-12 and LA volume >34 ml/m2.
- Grade II (restrictive physiology): E/A >2, DT<160 ms, E/e'>/=13 and LA volume >34 ml/m2.
- In case of overlap of these parameters so that no single category can be assigned the diastolic function will be categorized as abnormal.
The pulmonary artery pressure will be determined non-invasively on echocardiography by measuring tricuspid regurgitation jet velocity and adding the estimated right atrial pressure (15-17).
Pulmonary edema will be diagnosed either clinically by the presence of fine inspiratory crepitations on chest examination and high jugular venous pressure, and radio graphically by the presence of venous congestion and/or Kerley B-lines after confirming the finding by consultant radiologist oncall (18-20).
The vaso-occlusive crisis will be diagnosed clinically be the presence of the classical symptoms of pain and dehydration in the absence of alternative diagnosis (21-23).
Controls: The follow up echo (second echo) will be used as a baseline to compare the findings in the acute crisis to. As it is difficult to decide who of the patients with SCD will develop the acute crisis, we decided to recruit patients presenting in acute crisis and redo the echo as a follow up and use the follow up echo as a baseline looking at the same parameters.
Study Design Prospective cross sectional study Sample Size 50% probability of having the outcome of interest. Assuming 10% drop rate the number of needed subject would be 216 patients to achieving 95% confidence, 7 % margin of error.
Sampling Technique A consecutive inpatient admission to medical ward will be enrolled in the study according to inclusion and exclusion criteria mentioned above.
Data Management and Analysis Plan The SPSS for Windows 19.0 programme (SPSS Inc, Chicago, Illinois) will be used for statistical analysis. The chi-square test was used to analyze categorical variables and the Student's t test was used to analyze parametric variables. A p-value of 0.05 or less was considered statistically significant.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Sickle cell | – | –Patient who are admitted with sickle cell crises |
Who may qualify
- Ages
- 14 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Adult patient admitted to the hospital with vaso-occlusive crisis
Key inclusion criteria (3 listed)
- Patients older than 18 years
- Diagnosis of acute vaso-occlusive crisis due to sickle cell disease.
- Informed consent
Key exclusion criteria (2 listed)
- Congenital heart disease
- Long standing hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Sep 2012.
Related trials for Sickle Cell
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
Active, not recruitingObservational study
Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease
Sickle Cell Anemia, Sickle Cell Thalassemia
Enrolling by invitationPhase 4
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Pyruvate Kinase Deficiency, Anemia, Hemolytic
Active, not recruitingPhase 2
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
Sickle Cell Disease
RecruitingPhase 3
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Sickle Cell Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sickle Cell, run by King Abdullah International Medical Research Center at 1 site in Saudi Arabia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 13 Sep 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Dr Abdulsalam M Alaithan, MD (96635910000 ext. 33445, aithana@ngha.med.sa), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2012.